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Statement of translational relevance
The clinical benefit observed with drugs targeting oncogenic kinases is very often transient due to the appearance of resistance linked to secondary mutations in the target molecules, or to the activation of parallel pathways. Also, brain metastases lead to the progression of the disease when drugs do not reach the tumor site due to the presence of the blood brain barrier.
This study presents original data on the biochemical and biological characterization of NMS-E973, a novel second generation inhibitor of Hsp90. This non ansamycin compound has antitumor efficacy against a broad range of preclinical tumor models, including models of resistance to some recently approved kinase inhibitors such as vemurafenib and crizotinib. Furthermore, NMS-E973 shows antitumor activity against intracranially implanted tumor xenografts, consistent with its ability to penetrate the BBB. This feature highlights the potential of this new class of molecules with the ability to gain access to the brain, since the most advanced inhibitors of Hsp90 are not brain permeable.
Introduction
The molecular chaperone Heat Shock Protein 90 (Hsp90) is essential for the conformational stability and activity of many key oncogenic proteins, including kinases such as ErbB2, B-Raf, Alk, Flt3, EGFR, RET, KIT, PDGFR, MET, AKT but also transcription factors, telomerase, and other proteins that participate in the activation of the several biological pathways whose dysfunctional activation have been collectively described as constituting the hallmark traits of cancer (1). Based on this mechanism of action it is possible, by using a specific inhibitor of Hsp90, to induce the degradation of diverse client proteins and as a consequence to achieve a parallel block of multiple signaling pathways that results in cell death and inhibition of the growth of a broad range of tumors, as already described in several preclinical studies (2) .
For these reasons Hsp90 emerged in the last decade as a major therapeutic target and a great deal of efforts have been dedicated to the discovery of inhibitors, some of them currently under clinical evaluation (3) . After the identification of the initial Hsp90 inhibitors, in particular 17-AAG and other semi-synthetic ansamycin derivatives such as retaspimycin (4), a new group of fully synthetic second generation inhibitors were developed with improved preclinical efficacy and "drug-likeness".
Among the most advanced compounds, retaspimycin and the second generation representative ganetespib have shown significant clinical benefit, measured as RECIST-based partial responses at tolerated dosing regimens in Alk driven NSCLC and ErbB2-positive breast cancers, as single agents, or in combination with trastuzumab (5-7). The most frequent clinical toxicities described so far are hepatic for 17-AAG and its derivatives (6) , gastrointestinal and ocular for many second generation inhibitors (3), reported to be dependent on the schedule of administration and on the tissue distribution of the molecule (8) .
The clinical benefit observed with drugs targeting oncogenic kinases, such as the recently approved crizotinib (for Alk) and vemurafenib (for B-Raf), is very often transient due to the appearance of resistance linked to secondary mutations in the target molecules (9) , to the activation of parallel 5 pathways such as EGFR and C-Raf signalling (10) (11) (12) (13) , as well as to the intrinsic heterogeneity of the tumors. Also, in a relevant number of Alk related cases, disease progression due to brain metastases is suggested to be related to insufficient concentrations of the drug within the brain (14) . The high dependency on Hsp90 of Alk and B-Raf kinases, as well as of other kinases that are drivers of escape pathways, provides an additional mechanism to prevent and/or overcome resistance.
Here, we describe a novel potent and selective Hsp90 inhibitor, the isoxazole derivative NMS-E973, with antitumor efficacy against a broad range of preclinical tumor models, including tumors resistant to vemurafenib. Its very favorable features in terms of biochemical and cellular potency, broad efficacy spectrum, tumor retention and blood-brain barrier penetration, suggest a potential for clinical development also as second line treatment in tumors that have become resistant to molecular targeted agents, also in the presence of brain metastases as proven by the activity obtained in an intracranial tumor model.
Materials and Methods

Reagents and chemicals
NMS-E973, 5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methylpiperidin-4-yl)isoxazole-3-carboxamide was synthesized at Nerviano Medical Sciences S.r.l. laboratories. The synthesis has been previously reported (WO 2010/121963). NMS-E973 and other reference Hsp90 inhibitors were synthesized in house
Hsp90 binding and selectivity assays
The recombinant proteins have been expressed as His-tagged versions of the human Hsp90 (full length for assays and aa. 9-236 for structure determination), human Grp94 ATPase domain (aa. 69-337) and human Trap1 (aa. 26-end), following the published conditions (15) (16) (17) . Briefly, they have been expressed in Escherichia coli BL21(DE3) at 18°C for 16 hours, then the soluble proteins were purified by affinity chromatography on a Ni-Sepharose column (GE Healthcare). After the overnight cleavage of the hexahistidine tag by the site-specific protease PreScission (GE Healthcare), the final purification was achieved by size exclusion chromatography (Superdex 200, GE Healthcare), and the proteins were stored in PBS buffer containing 10% glycerol and 0.1 mM EDTA.
A commercially available FITC-Geldanamycin (InvivoGen) was used as probe in a Fluorescence Polarization (FP) assay, after its reduction as described elsewhere (18) .
For competition experiments a protein concentration of 5 nM for Hsp90 and of 200 nM for Trap1 were mixed with 0.5 nM probe (final concentrations). After incubation the DMSO compound solution was added to the mixture. The plate was incubated for 18 hours at r.t. and then the FP signal was measured. Data were fitted with the program Dynafit version 3.28.039 (BioKin Ltd, Watertown, MA) or SigmaPlot (SSI, San Jose, CA) using the mathematical equation for competitive binding of two ligands to the receptor (19).
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We synthesized in house a Grp94 binding probe by coupling NMS-E973 to the fluorophore Atto-610 (Atto-Tec GmbH -Germany). For competition experiments Grp94 was mixed to the probe at a final concentration of 50 and 20 nM respectively. FP displacement assay for Hsc70-FL was set up using a commercially available probe N 6 -6-aminoHexyl-EDA-ATTO-590-ATP (JenaBioScience -Germany).
Determination of NMS-E973 binding kinetics to Hsp90 was performed using Biacore T100 with the approach of the kinetic titration as previously described (20) . The data were fitted using the 1:1 kinetic titration model of BIAevaluation software.
NMS-E973 was tested against a panel of 52 diverse kinases as previously described (21) . The following in house produced kinases were tested: ABL, ACK1, AKT1, Alk, AUR1, AUR2, BRK, CDC7, CDK2/CYCA, CHK1, CK2alpha/beta, eEF2K, EGFR1, ERK2, FAK, FGFR1, Flt3, GSK3beta, Haspin V473-K798, IGFR1, IKK2, IR, JAK 1, JAK2, JAK 3, KIT, LCK, MELK, MET,   MK2, MPS1, MST4, NEK6, NIM, P38alpha, PAK4, PDGFRb, PDK1, PERK, PIM1, PIM2,   PKAalpha, PKCbetaII, PLK1, RET, SULU1, SYK, TRKA, TYK 2, VEGFR2, VEGFR3, ZAP70 .
Crystallography
Crystallization studies were performed using the N-terminal domain of Hsp90α (aa. 9-236). Crystals of the N-terminal domain of Hsp90 in complex with NMS-E973 were grown using the hanging-drop vapor diffusion method from a solution of 20% MPEG 2000K, 0.2 M Magnesium chloride 0.1 M Cacodylate pH 6.5 at 4°C. The protein was concentrated at 25 mg/ml and compound was added to a final concentration of 2 mM. For data collection, the crystals were transferred to drops containing the equivalent mother liquor with 25% glycerol. Diffraction data were collected at the ESRF (Grenoble, France) on beamline ID23-2. Data were processed using the HKL package (22) . The space group is P21. Model building was done using Coot (23) and refinement was done with
RefMac (24) . The coordinates have been deposited in the Protein Data Bank with code 4b7p
together with structure factors and detailed experimental conditions. 
Cell culture
Human cancer cell lines were obtained either from the American Type Culture Collection (ATCC) or from the European Collection of Cell Culture (ECCC). Cells were maintained in the media at serum concentrations recommended by the suppliers in a humidified 37°C incubator with 5% CO 2 .
Cell line authentication
All cell lines were profiled using DNA fingerprinting technology (AmpFlSTR Identifiler Plus PCR Amplification kit, Applied Biosystems) according to the manufacturer's protocol. The kit amplifies simultaneously 15 tetranucleotide repeated loci and the amelogenin gender marker in a single assay.
The short tandem repeat profiles of the analyzed cell lines were compared with DNA fingerprinting databases (e.g., ATCC and DMSZ). All the analyzed profiles showed a similarity higher than 80%.
Accordingly with many published studies (25, 26) , this is the suggested threshold to declare the correspondence between the examined cell line and the external reference. All cell lines are routinely confirmed at 6-month intervals.
Cell proliferation Assay
Exponentially growing cells were seeded in complete medium in a 384-well plate format. 24h after seeding, cells were treated with compounds dissolved in 0.1% DMSO, at different concentrations.
The cells were incubated at 37°C and 5% CO 2 and at the end of treatment time the plates were processed using Cell Titer-Glo assay (Promega) following the manufacturer's instruction. CellTiterGlo is a homogenous method based on the quantification of the ATP present, an indicator of metabolically active cells. Briefly, 25 μl reagent solution is added to each well and after 5 minutes of shaking microplates the luminescent signal is read by Envision (PerkinElmer) luminometer.
Inhibitory activity was evaluated comparing treated versus control data using sigmoidal equation on Assay Explorer (Symix) program. For combination assays, NMS-E973 and drug solutions, prepared immediately before use, were added to the cells in scalar doses, in 7 point dose response curves at constant ratios, employing a separate pipetting step for each drug. When sequential, rather than simultaneous combinations were studied, the first drug was added to culture 24 hours after cell seeding, and the second drug 48 hours after seeding (i.e. at Time = 24h). At Time = 72h, cells were lysed using 50 ul/well of Cell Titer-Glo reagent solution (Promega).
The data were expressed as percentage of viability versus DMSO controls and analyzed using a proprietary software (Beremiz) according to the Chou Talalay equation (27) . Combination indices (C.I.) were calculated for mutually nonexclusive drugs where a C.I. of <0.3 indicates strong synergism; 0.3-0.8 synergism, 0.8-1.2 additivity; 1.3-3 antagonism; >3 strong antagonism.
Cell-based assays
The mechanism of action of the compound was investigated using cell lines treated for 24 hours with compounds at the indicated concentration of DMSO as control. Client protein degradation was determined by Western blot analysis, using DMSO as a control. Immunoblotting was done according to standard procedures (28) Intravenous treatments started the day after randomization, with different schedules as described.
Tumor dimensions were measured regularly using Vernier calipers and tumor volume was calculated according to the following formula: length (mm) x width 2 (mm)/2.
The percentage of tumor growth inhibition (%TGI) was calculated as follows:
Toxicity was evaluated based on body weight reduction. At the end of the experiment, mice were sacrificed and gross autopsy findings were reported. Tumor-free (TF) animals at 90 days after tumor implant were considered cured.
For the leukemia studies, female severe combined immunodeficient (SCID) mice (Harlan) were A pharmacokinetic and pharmacodynamics (PK/PD) approach, based on a previously published model (29, 30) was applied to the efficacy data of NMS-E973. This model links the dosing regimen to the tumor growth dynamics independently from the schedule and levels of dose. A quantitative estimate of the drug potency is assessed through the parameters k 2 , the proportionality factor linking the plasma concentration to the effect, and C T , which provides an estimate of the steady-state drug concentration in plasma (C ss ) to be maintained for observing tumor stabilization.
Mean tumor volume of treated group %TGI = 100 -___________________________________________ x 100 Mean tumor volume of control group
Pharmacokinetics
The PK of NMS-E973 was investigated in an ancillary group of three tumor-bearing mice. Blood samples for the pharmacokinetic assessment were collected, and the drug was assayed in plasma using liquid chromatography tandem mass spectrometry techniques (29) . The PK of NMS-E973 was evaluated using a two compartment model after single IV administration of 10 mg/Kg.
Data Analysis
Winnonlin Program (Pharsight) was used both for compartmental PK and PK/PD analysis.
Parameters were estimated by using weighted nonlinear least squares (with weight 1/y 2 observed ).
In vivo Imaging of A375-LUC intracranially implanted
Intracranial model
Balb/c male nude mice, aged 6-8 weeks, were anesthetized and stereotactically implanted in the caudate nuclei region with 1x10 inserted into the radiofrequency coil (diameter 38 mm) inside the magnet. T2-weighted coronal scans (RARE: TR=5000 ms; TEeff=57 ms; rare factor=8; 4 averages; FOV=2.5*2.5 cm 2 ; Sl.
Thickn.=1 mm; matrix=256*128; acq. time=5 min 20sec) were acquired to better visualize tumors.
A macro was used to calculate total tumor volume, starting from the bidimenisonal area of all contiguous slices and slice thickness. 
Results
NMS-E973 is a potent and selective inhibitor of HSP90
A fragment-based approach coupled to an intensive medicinal chemistry effort led to the identification of the isoxazole derivative NMS-E973 (WO 2010/121963), a novel potent Hsp90 inhibitor structurally unrelated to ansamycins ( Figure 1A and Supplementary Figure S1 ).
NMS-E973 binds to the ATP binding site of Hsp90α with a DC 50 of <10 nM in a FP displacement assay. Since this assay has a sensitivity limit close to the nanomolar concentration of the Hsp90 protein used in the assay, we used a direct binding method, Surface Plasmon Resonance analysis, to define a more accurate K D of 0.346 nM. We then studied the selectivity of the compound towards Grp94 and Trap1, the structurally related endoplasmic reticulum and mitochondrial isoforms of Hsp90, which are also reported to be overexpressed in tumors and possibly involved in cancer development (31) (32) (33) . We calculated a K D of 4.5 nM (>10 fold selectivity) for Grp94, while a K D of 670 nM (∼200 fold selectivity) was obtained for Trap1. No activity was observed when the compound was tested against a panel of 52 diverse protein kinases, as well as against the biologically related ATPase Hsc70 (IC 50 >10 μM).
As expected based on its high biochemical potency, the crystal structure of NMS-E973 bound to the N-terminal domain of Hsp90 in the ATP binding site ( Figure 1A) shows a broad network of hydrogen bonding interactions, in addition to those between Asp93 and the phenolic hydroxyl already described for other inhibitors. The resorcinol moiety forms a network of water-mediated interactions with the neighborly residues Gly97, Ser52 and Leu48. The 4-nitro-phenoxy-phenyl group linked to the resorcinol residue is located near a flexible region formed by residues 103-111 and causes its partial rearrangement without, however, inducing the opening of the lipophilic pocket 
NMS-E973 inhibits cancer cell proliferation and induces client protein degradation
When profiled against a panel of 140 human tumor cell lines of various tissue origins and molecular background, NMS-E973 shows a widespread antiproliferative activity, with an average IC 50 of 1.6 μM and 15 cell lines with an IC 50 < 100 nM. (Figure 1B and Supplementary Table S1 ).
As expected due to the broad mechanism of action of Hsp90 inhibitors, it was not possible to unambiguously associate the pattern of sensitivity observed across the cell panel with mutations in a single gene. However, we observed that all of the most sensitive cell lines are driven by the disregulated activation of known oncogenic pathways (Table 1) The AKT and MAPK pathways were also simultaneously inhibited in the A2780 ovarian cancer cell line upon treatment. Again, these modulations were associated with the feedback induction of Hsp70 expression ( Figure 1C ).
Pharmacokinetics and tissue distribution of NMS-E973
In order to explore the possibility to use NMS-E973 for in vivo experiments, its pharmacokinetic properties were investigated in mice. When administered intravenously to three mice at 10 mg/Kg, the compound resulted suitable for in vivo administration with high exposure levels, compatible with biological activity, a half life of >5 hours and a high volume of distribution, associated to a moderate systemic clearance (Figure 2A ). The kinetics of tissue distribution of the compound in plasma, brain, liver and tumor over time were determined in mice xenografted with the A375 tumors after treatment with the active dose of 60 mg/Kg ( Figure 2B ). Significant levels of NMS-E973 were detected in tumors for three days, with a more rapid elimination from liver and plasma. Interestingly, significant concentrations of NMS-E973, exceeding those observed in plasma, were observed in brain, indicating the capacity of the compound to penetrate the blood brain barrier. 
NMS-E973 inhibits
intermittent schedule 3-1-3 to large regrown tumors (0.5 g), was again efficacious, with tumor regression and 1/7 mice tumor free at day 92 ( Figure 2C ).
To study the ex vivo mechanism of action, the compound was administered at 60 mg/Kg bid, and at different time points after the second administration, biomarker modulation was investigated in lysates from A375 xenograft tumors. Inhibition of Hsp90 resulted in decreased MAPK pathway activation at early time-points (up to 6-12 hours), followed at later time points (12-24 hours) by induction of apoptosis, measured as caspase 3 activation, and upregulation of Hsp70 levels. Most biomarkers returned to control levels after 24-48 hours, although significant recovery of AKT and BRAF was observed by 12 hours ( Figure 2D ). In order to achieve sustained modulation of these biomarkers we therefore conducted efficacy experiments in which we administered the compound every 12 hours (bid). Based on the observed presence of compound in the brain, the efficacy of 
Treatment with NMS-E973 is active in A2780 xenograft tumors
Since the ovarian carcinoma A2780 cell line is one of the most sensitive to treatment with NMS-E973 in vitro, the efficacy of the compound was tested in vivo in two experiments using different schedules and doses, and a PK/PD approach was applied based on a previously published model that links the dosing regimen to the tumor growth dynamics, generating an algorithm able to estimate and predict the efficacy in different conditions (29) . As shown in Fig. 4A , treatment with either 30 or 60 mg/Kg of NMS-E973 for 10 consecutive days resulted in significant tumor growth delay (TGI 53% and 74%, respectively). Based on these results, an algorithm was generated that was able to accurately fit the data ( Figure 4A, lines) . It can be used to calculate the C T parameter, which provides an estimate of the steady-state plasma drug concentration needed to observe tumor stabilization. As predicted by the algorithm, treatment with either 30 or 60 mg/Kg bid with one cycle of the intermittent 3-1-3 schedule resulted in higher efficacy (TGI 68% and 91%, respectively; Figure 4B ) associated to a moderate body weight loss (4.5 and 7.7%, respectively). Fitting the data on the A375 and A2780 xenograft tumor models we obtained similar C T, around 2-2.3 μΜ ( Figure   4C ). This parameter is helpful to guide preclinical inhibitor development and can help to estimate the active dose in humans.
NMS-E973 induces tumor eradication of a Flt3 ITD dependent leukemia model
The in vivo antitumor efficacy of NMS-E973 against the MOLM-13 AML cell line, driven by the The same treatment schedule was highly efficacious also when the cells were systemically injected in mice, with 9/10 animals alive at day 120 at the end of treatment ( Figure 5B ). This activity was superior to that observed for sunitinib, highly active against Flt3, when administered at 40 mg/Kg daily for 20 consecutive days (death of all animals by day 41; Figure 5B ). Although we did not perform ex vivo biomarker modulation studies in this experiment, the ability of NMS-E973 to induce degradation of Flt3 ITD was confirmed in MOLM-13 cells in vitro ( Figure 1C )
NMS-E973 is active in resistance models
Emergence of resistance is a common feature of targeted therapy with kinase inhibitors, often resulting from mutations of critical residues in the ATP pocket, such as those observed after In melanoma, resistance to treatment with vemurafenib and the short duration of responses have not been associated to B-Raf kinase mutations so far, but they are linked to the activation of alternative signaling pathways (10, 11) . Also in colon, an escape mechanism from B-Raf inhibition through the activation of EGFR signaling has been suggested. Infact, B-Raf-mutant colorectal cancer cell lines have been described to harbor higher basal levels of EGFR/pEGFR compared to melanoma cells (12) , with an increase in pEGFR after vemurafenib treatment (13) . Since all the activated pathways 
towards a suitable therapeutic window, and by the challenge to identify the most sensitive patient population. However, there is currently a new wave of interest in this field linked to the promising clinical activity observed recently with retaspimycin and ganetespib in Alk driven NSCLCs (5, 6) and in ErbB2-positive metastatic breast cancers (7, 42, 43) , that allowed to identify clinical settings in which schedule optimization of agents with higher potency resulted in permissive conditions for selected Hsp90 inhibitors.
Here we showed the characterization of NMS-E973, a lead compound belonging to a novel isoxazole series structurally unrelated to ansamycins. NMS-E973 binds with high potency and selectivity to the ATP binding pocket of Hsp90α, shows broad antiproliferative activity in vitro This activity was superior to that of the multikinase inhibitor sunitinib in the same experiment, and 
compared favorably with the activity of AC220 (45), the most potent and selective Flt3 inhibitor described so far, tested in the same model (data not shown). Resistance mutations to Flt3 inhibitors in clinics are beginning to emerge, such as the D835Y mutation in the tyrosine kinase domain (45) , raising the opportunity for future studies with NMS-E973 in this setting.
Metastases to vital organs of difficult surgical access are the ultimate cause of death when not controlled, and brain metastases are the most life-threatening among the secondary localizations of cancers such as melanoma, NSCLC and breast cancers for their unresponsiveness to chemotherapeutic treatments. Brain cancers represent another crucial unmet medical need, and although the presence and function of the blood-brain barrier in brain tumors is still poorly understood, it is likely that small tumors could be protected from therapeutics by the barrier itself, creating a "sanctuary" site (46, 47) . Among Hsp90 inhibitors, SNX-5422 does not reach the brain (48) , the efficacy of AUY-922 in brain cancers has been restricted so far to subcutaneously implanted glioblastomas due to low BBB permeability (49) , and only CUDC-305 (50) 
